OrdinaryAverageGuy1 with a little help from his friends Cardu and Sharkfood have put up a number of posts to make the normal reader move on to something else. Their posting encouraged me to repeat my posts Deception with a minor change to the intro and Reply to Cardu With Apologizes to the Bard. It is pasted at the end of this post.
Next to whining about Brad, the other most common trick of the buy side manipulators is to bury posts supporting Oncolytics’ stock price in the archives; never to see the light of day again. They have the advantage of many user names to give the impression that they control the discussion board.
Unfortunately for them, the people that they want to deceive can think for themselves. I do agree that some readers find my persistent posting a pain in the neck. My message is as repetitive as the whining about Brad. There is very little new news on this discussion board. The discussion is really a change in the form of repeating old news. It is much like the Globes’ coverage of the possible pending Federal Election for the past two years. Or, is it three? I rarely read past the headlines. Besides being a source of misinformation, this is another reason why I will not participate in this discussion board once the stock price for ONC reflects fair value. I only post to protect my investment. I liked it when ONC went up in value last year from below $3.00 when I started posting.
Is it only me that want the share price of ONC to reflect its fair value? I understand the greed and dishonesty of the buy side manipulation. Why pay over $10 per share when you can deceive retail investors into selling for $6.30. There are many retail investors who do not read or hear my message of hold onto your shares. There is no reason to sell. Analysts at RBC Capital Markets have conservatively Oncolytics’ share price in 2016 at $26.52. 2016 is the year that they predicted Reolysin will be commercially available. Mid year 2011, this year, is when they expect partnership agreements to be announced. Analysts for other firms covering Oncolytics (5) are equally optimistic and raising pricing targets. These are credible analysts with expertise and access to information.
I have no intention of selling until after the partnership deals are announced. Look at the historic stock charts for DNDN and AMGN on the NASDAQ. You see the cliff as the stock price jumped on good news. Was the market unaware of this pending news and taken by complete surprise? No, the market was deceiving the misinformed retail investor until the last possible moment. They sold too soon because they put their faith in the market price being honest.
I am not stressed by my over weighted margin position in Oncolytics. I am confident that RBC CM’s modeled forecast of $26.52 is conservative. DNDN and AMGN are examples that overnight returns of 400% are possible. There are 24 trials for Reolysin listed on the Oncolytics website. Independent practitioners from different countries have conducted these trials. The US NCI is funding and controlling 2 of them. It is not random chance that Reolysin has met and will continue to meet its end points at trials. The science works. It has been researched and duplicated by many independent practitioners. The pivotal head and neck trial is unique since the end point is based on achieving a Bayesian determined end point. Based on the results of 80 patients in Phase I of the trial, the Phase II endpoint will be defined with over an 80% probability for success.
I want to thank the readers who have supported my efforts to stop this buy side manipulation. I encourage all existing retail investors to hold onto their shares and consider leveraging their position by buying on margin.
For new retail investors and their advisors, read the post below so you have the full story before reading OrdinaryAverageGuy1’s posts. It does not take too much thought to read through the deceit of whining about Brad, saying the market price is right, and not caring about a declining stock price. Note their little tricks having reputation ratings and voting on posts. I have had high 4 and 5 ratings after over 100 hits to be downgraded to a 3 or lower within another 10 hits. The case for investing in Oncolytics is a strong one.
For OrdinaryAverageGuy1, the answers to your questions are: Never as long is margin is available; Brad’s disclosure on the pivotal trial was 80%; RBC Capital Markets forecast of $26.52 in 2016 and the current market cap for the stock price being manipulated; and 2.
LOL
JLGemini
Reply to Cardu With Apologizes to the Bard Posted Feb 25
Cardu, I come to credit OrdinaryAverageGuy1, not to discredit him. Is it nobler in the mind to abuse a position of power and spread deceit for material gain, or to be honest? To be honest, or not to be?
You endorse OrdinaryAverageGuy1 as an honest person. “Your points are very well taken. It may be that BT has a "vision" regarding the development of this treatment, a vision he won't share with the rest of us plebeians. Be careful how you talk about BT. Your honest opinion, as you see it, could be construed as "whining" by a certain member of this board. That attitude = arrogance, in my honest opinion.”
Doth your poor plebeian soul say that the only “honest post” must discredit Brad and misinform the retail investor? You praise OrdinaryAverageGuy1 for a post asking one question on the lack of pivotal trials and expecting an answer to address his concern regarding the life of patents. “I get all that, but with the number of phase II trials ONC has completed over the years one would expect a phase III to follow instead of more phase II trials in different clinical applications...if the phase II trials were successful. The clock is ticking on ONC's patents. I have nothing for or against the CEO. As a shareholder and a person who wants to see effective new cancer treatments brought to market, I'm beginning to wonder why the company isn't advancing this product to the final stage of clinical trials.”
Your cloak reflects your honesty. RJC2827 rebuked OrdinaryAverageGuy1 for not recognizing the current pivotal trial for head & neck. The expertise of your cadre that includes CravenRaven, Sharkfood, and others are quick to point to the minute of Brad’s presentations where he said something that displeases you. I note the absence in your response to address OrdinaryAverageGuy1’s concern but the deceitful intent to heap scorn on a humble servant of the retail investor. Your failure to mention Brad saying that Oncolytics has patent protection until 2028 or 2048 or something like that speaks to character of the cadre. Brad also revealed that there are some corporate secrets that they have deferred seeking patents. I suspect that Mary Ann Dillahunty, VP Intellectual Property, has provided prudent counsel in maximizing Oncolytics’ intellectual property value. The analyst covering Oncolytics for RBC Capital Management were not concerned about patent protection when they modeled a stock price for Oncolytics of $26.52. No, they took the time to say that many factors could make their forecast conservative. As an investor, I look forward to the day Oncolytics trades above $26.52. Why do you rejoice at the current market price? The current market cap valuation is less than the cash advance to BioVex shareholders received from Amgen on their potential billion dollar deal.
No, I praise how the buy side manipulators have weaved their web of deceit over the years. Do not stand as an honest man and scream into the darkened night. Take many forms so you can sing as a chorus to jeer anyone saying a kind word. Deceit can not exist until the cadre proclaims it so. Take turns refuting the existence of a buy side manipulation. Bring forward ghosts of the past, like TMM9 and JJG001, to show the strength of the buy side deceit. Be the witches from Macbeth to create new pawns, like OrdinaryAverageGuy1. He has disclosed, with significant importance and flair, that he has invested in Oncolytics since 2003. According to his Stockhouse profile, he joined the discussion board last Wednesday, the 24th of February to post a misleading question. The witchery occurs by his reputation rating of 1. It is through manipulators’ trickery that his quality and participation ratings are 1. OrdinaryAverageGuy1 accomplished this feat by only making 2 posts that have only been seen by 234 hits.
Retail investors do not be deceived. Owning thousands of shares in Oncolytics today will make you financially stronger tomorrow as the world unfolds as the analysts predict. Do your other investment options offer over a 400% increase with over an 80% probability of success in two years?